Moreover, the pan-PI3K inhibitor buparlisib (BKM120) displayed antileukemic effects in primary patient T-lymphoblasts and prolonged survival in subcutaneously injected murine models of T-ALL [109]. Here, PIK3CA is linked to acute lymphoblastic leukemia.